GlycanAge, based in The Catalyst on Newcastle’s Helix development, is bringing a whole new aspect of human biology to consumers with a test that analyses sugar molecules to determine your biological age.

Looking deeper into the predictive capabilities of the glycans, the GlycanAge team has been designing another take-home blood test, MenoAge, which has the potential to diagnose perimenopause and menopause, supporting women in the UK and across the world to receive an accurate diagnosis and optimise treatment.

The announcement follows a study published earlier this month in iScience, led by a team of researchers from GlycanAge’s parent company, Genos Glycoscience Research Laboratory in Croatia - as well as Newson Health Menopause & Wellbeing in Stratford upon Avon and King’s College London – who followed nearly 2,000 women for 15 years during their transition from pre-menopause to post-menopause, analysing levels several times during that period.

Read more: Fujifilm vaccine investment in Billingham

The study found changes in the glycome during perimenopause, indicating its composition could potentially be used as an early predictor.

Dr Cristina Menni, from Kings College, London, said: “Perimenopause is poorly diagnosed due to highly irregular hormonal cycles and symptoms that can last for as long as 15 years. Currently, there is no accurate diagnostic test, but adding an easily quantifiable early biomarker could be a valuable improvement to current clinical praxis.”

Prof Gordan Lauc, chief scientific officer at GlycanAge and honorary professor at King’s College London, said: “A good biomarker of biological age needs to show relevance for real-life biology. In this respect, GlycanAge is so far the best biomarker. By tracking 2,000 women for 15 years, we just showed that perimenopause period is associated with much faster glycan ageing.

“MenoAge is intended to become a test for diagnosing perimenopause in an accurate, rapidly deployable, and cost-effective manner. Early diagnosis of menopause will lead to prompt treatment, thus preventing and alleviating symptoms associated with ageing, with a wide range of health and societal benefits.

“In the UK, timely treatment of perimenopause could save the NHS over £500 million. A validated diagnostic biomarker, therefore, has game-changing potential for the menopausal care pathway and could revolutionise the management of female health and ageing.”

The team is currently in the process of having MenoAge recognised by the NHS and the National Institute for Health and Care Excellence (NICE).

Since moving its headquarters in 2021 to The Catalyst, which is home to the National Innovation Centre for Ageing and a dynamic cluster of businesses focussed on life sciences, GlycanAge has a wealth of collaborative opportunities on its doorstep and is in the perfect environment to continue translating research discoveries into products.

The Catalyst is located in the heart of the £350million Newcastle Helix development which brings together businesses, industry leaders, researchers and academics.

Rebecca Robinson, centre manager at The Catalyst, said: “GlycanAge is an incredibly innovate business and we’re proud they have chosen Newcastle and The Catalyst as a base to grow and develop their product, as they lead the way in biological ageing.”

 

Keep up to date with all the latest news on our website, or follow us on Facebook, Twitter and Instagram.

You can also follow our dedicated County Durham Facebook page for all the latest in the area by clicking here.

For all the top news updates from right across the region straight to your inbox, sign up to our newsletter here.

Have you got a story for us? Contact our newsdesk on newsdesk@nne.co.uk or contact 01325 505054